Bank of America just raised its EUR/USD forecast
HONG KONG - Hutchmed (China) Limited (NASDAQ/AIM:HCM; HKEX:13), a biopharmaceutical company, has announced a delay in the dispatch of a circular regarding its previously announced divestment of a 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited. The circular, which was initially expected to be sent to shareholders by today, will now be dispatched by February 28, 2025.
The delay is due to GP Health Service Capital requiring additional time to designate the GP Purchaser Fund and the Designated Purchaser, particularly considering the Chinese New Year holidays. This adjustment in the timeline was communicated in a regulatory announcement to the Stock Exchange of Hong Kong Limited, in accordance with Chapter 14 of the Rules Governing the Listing of Securities.
The transaction, valued at US$608 million, was first announced on January 2, 2025, and is subject to customary closing conditions and potential waivers. The completion of the deal remains uncertain until these conditions are fully met. Shareholders and potential investors of Hutchmed are advised to exercise caution when dealing in the company's shares and securities.
Hutchmed specializes in the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company has successfully marketed its first three medicines in China, with one also approved in the US, Europe, and Japan.
The information regarding the delay is based on a press release statement provided by Hutchmed. The transaction's final outcome will be closely watched by investors, as it represents a significant divestment for the company. The eventual proceeds from the sale could impact Hutchmed's investment in its core business areas and its ability to further innovate in the biopharmaceutical industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.